article thumbnail

Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery

DrugBank

In fact, it's one of the most exciting areas in drug research today. With billions in funding and innovative research, we're starting to see strategies that can tackle these tough targets. One approach is to look beyond the traditional drug molecule.

article thumbnail

Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment

Sygnature Discovery

Sygnature Discovery is delighted to announce that its customer, River BioMedics , has raised an additional €2M in seed funding to continue its life-saving cardiovascular drug research. The biotech’s aim is to develop medicines that treat the underlying cause of heart failure rather than merely treating the symptoms.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article EMA Thank You With all nitrosamines deadlines passed, EMA updates its guidelines

Agency IQ

These API-derived nitrosamines are referred to as Nitrosamine Drug Substance Related Impurities (NDSRIs) and represent an unprecedented development with manufacturing, quality, and product safety implications. In a study of more than 12,000 small molecule drugs , researchers found 40.4%

article thumbnail

Analysis Life Sciences Thank You FDA lays out new assessment framework for certain nitrosamines

Agency IQ

In a study of more than 12,000 small molecule drugs , researchers found 40.4% This means that entire classes of critical drugs (like ACE inhibitors and beta blockers) containing secondary or tertiary amine moieties in their API molecular structures are technically nitrosamine precursors.

FDA 40
article thumbnail

Bayer, Broad Institute Extend Cardiovascular Drug Research Pact

The Pharma Data

By leveraging large-scale genomic datasets and functional assays in human cardiomyocytes, researchers from Bayer and the Broad Institute are working to map the complex gene networks that drive disease progression in DCM and other cardiovascular disorders.

article thumbnail

Using clinical genomics and AI in drug development to elevate success

Drug Target Review

Drugs that were developed and commercialised 30+ years ago were relatively simple small molecules. Todays small molecules are far larger, more complex, and chase highly specific (and difficult to hit) targets, thereby increasing the chances of undesired side effects.